• Medivir AB, of Stockholm, Sweden, said Bristol-Myers Squibb Co., of New York, terminated development of the preclinical HIV compound MIV-170 because it did not meet the desired profile. MIV-170 is a polymerase inhibitor that Medivir licensed to BMS in September 2006. Medivir already had discontinued development of that product and others from the class. Under the deal with BMS, Medivir received an up-front payment of $7.5 million and was eligible to receive up to $97.5 million in development and regulatory milestones, plus double-digit royalties on resulting sales.

• Merck Serono SA, of Geneva, said the Civil Court of Basel cancelled all remaining publicly held shares of the company, and annulled all outstanding rights to acquire such shares. Therefore, Merck now holds 100 percent of the shares of Merck Serono. Merck Serono's shares will be delisted from the SWX Swiss Exchange July 18. Affected holders of the publicly traded shares of Merck Serono will receive the same compensation per share as those who tendered their shares when Merck KGaA acquired Serono SA.

• Omrix Biopharmaceuticals Inc., of New York, said the FDA approved its use of Cryoprecipitate from Talecris Biotherapeutics Inc., of Research Triangle Park, N.C. The product is a plasma fraction containing coagulation proteins and the raw material from which Omrix manufactures BAC, the fibrinogen component of its marketed fibrin sealants Evicel and Quixil, and the Fibrin Patch product candidate. It is used in the manufacturing process and is expected to allow Omrix to lessen its dependence on plasma, while increasing margins in the long term.

• Tripos Inc., of St. Louis, said it was notified by Nasdaq that its common stock was delisted effective Friday. The stock now is trading on the Over-the-Counter Bulletin Board.